Leo Pharm Company Profile

What is the competitive landscape for LEO PHARM

LEO PHARM has thirteen approved drugs.

There are thirteen US patents protecting LEO PHARM drugs.

There are two hundred and twelve patent family members on LEO PHARM drugs in thirty-eight countries and twenty supplementary protection certificates in fourteen countries.

Summary for Leo Pharm

International Patents:	212
US Patents:	13
Tradenames:	9
Ingredients:	8
NDAs:	13
Drug Master File Entries:	2
Patent Litigation for Leo Pharm:	See patent lawsuits for Leo Pharm

Drugs and US Patents for Leo Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	ANZUPGO	delgocitinib	CREAM;TOPICAL	219155-001	Jul 23, 2025		RX	Yes	Yes
Leo Pharma As	DOVONEX	calcipotriene	OINTMENT;TOPICAL	020273-001	Dec 29, 1993	AB	RX	Yes	No
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589-001	Oct 16, 2015		RX	Yes	Yes	10,130,640*PED				Y
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes	9,211,259
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589-001	Oct 16, 2015		RX	Yes	Yes	10,688,108
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes	7,700,076		Y
Leo Pharma As	PROTOPIC	tacrolimus	OINTMENT;TOPICAL	050777-001	Dec 8, 2000	AB	RX	Yes	Yes

Expired US Patents for Leo Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Leo Pharma As	DOVONEX	calcipotriene	CREAM;TOPICAL	020554-001	Jul 22, 1996	RE39706
Leo Pharma As	PROTOPIC	tacrolimus	OINTMENT;TOPICAL	050777-002	Dec 8, 2000	5,665,727
Leo Pharma As	FINACEA	azelaic acid	GEL;TOPICAL	021470-001	Dec 24, 2002	4,713,394
Leo Pharm	DOVONEX	calcipotriene	SOLUTION;TOPICAL	020611-001	Mar 3, 1997	4,866,048
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	SUSPENSION;TOPICAL	022185-001	May 9, 2008	6,787,529
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015	8,900,554
Leo Pharma As	DOVONEX	calcipotriene	CREAM;TOPICAL	020554-001	Jul 22, 1996	4,866,048

Paragraph IV (Patent) Challenges for LEO PHARM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Topical Solution	0.01%		2006-05-19
	Topical Foam	15%		2017-09-14
	Ointment	0.1%		2010-09-09
	Ointment	0.005%/0.064%		2010-03-31
	Gel	15%		2012-07-27
	Gel	0.05%		2010-12-01
	Ointment	0.03%		2010-11-22

International Patents for Leo Pharm Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2011013785
Israel	222865
Denmark	2494959
World Intellectual Property Organization (WIPO)	2007007208
New Zealand	603470
World Intellectual Property Organization (WIPO)	2006003481
Israel	188602

Supplementary Protection Certificates for Leo Pharm Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2460806	2590009-3	Sweden		PRODUCT NAME: DELGOCITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE THEREOF; REG. NO/DATE: EU/1/24/1851 20240923
2460806	C20250012	Finland		PRODUCT NAME: AKORAMIDIS;REG NO/DATE: EU/1/24/1906 11.02.2025
2460806	LUC00381	Luxembourg		PRODUCT NAME: DELGOCITINIB SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1851 20240923
2435024	2021C/518	Belgium		PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210
2460806	122025000013	Germany		PRODUCT NAME: DELGOCITINIB IN ALLEN DURCH DAS GRUNDPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/24/1851 20240919
2460806	CR 2025 00010	Denmark		PRODUCT NAME: DELGOCITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ELLER ET SOLVAT DERAF; REG. NO/DATE: EU/1/24/1851 20240923
2435024	202140009	Slovenia		PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Leo Labs
• Leo Pharm
• Leo Pharma As

Pharmaceutical Competitive Landscape Analysis: Leo Pharma – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

Leo Pharma is a global specialty pharmaceutical company focused on dermatology, dermatology-related immunology, and critical care. Known for its emphasis on skin health, the company operates across multiple regions with a significant presence in North America, Europe, and emerging markets.

What Is Leo Pharma's Market Position?

Leo Pharma ranks among the top private dermatology

companies. It holds a substantial share in niche segments—particularly psoriasis, eczema, and skin infections. The company's core markets include North America, Europe, and select Asian countries, representing approximately 70% of its revenue.

Revenue and Market Share

Metric	2022 Figures	Notes
Estimated global revenue	$2.1 billion	Growth rate of 3% YoY
Dermatology segment revenue	$1.8 billion	85% of total revenue
Market share in psoriasis drugs	12-15%	Among private companies, second behind Johnson & Johnson
Presence in critical care markets	Niche, focusing on antibiotic and wound care products	Accounts for approximately 15% of revenue

Competitive Standing

Leo Pharma's positioning is strengthened by its niche focus and targeted R&D pipeline. It competes primarily against Johnson & Johnson, Novartis, and AbbVie in dermatology. Its stronghold lies in specific indications where it maintains high market share but faces intense competition from larger multinationals in broader dermatology segments.

What Are Leo Pharma’s Core Strengths?

Focused Niche Portfolio

Leo Pharma concentrates on dermatology, particularly psoriasis, eczema, and bacterial skin infections. This specialization results in high product expertise and tailored therapeutic offerings.

Proprietary Innovation and R&D Pipeline

The company invests approximately 15% of its revenue into R&D, about $300 million annually. Its pipeline includes biologics and small molecules targeting difficult-to-treat dermatological conditions. Key products approaching late-stage development include:

• LJX009: A biologic for severe psoriasis.
• LMS115: An oral small molecule for eczema.

Strong Regional Presence in Europe and North America

Leo Pharma maintains robust sales channels via direct subsidiaries and partnerships. Its European operations contribute roughly 50% of revenue, with North America accounting for 30%, enabling it to maintain sustained growth and market influence.

Strategic Mergers and Acquisitions

Leo Pharma's acquisition of smaller biotech firms has bolstered its pipeline. Notably, the 2021 acquisition of SkinTech, a startup focused on skin microbiome therapies, diversified its product offerings and opened opportunities in emerging areas.

Clinical and Scientific Leadership

Leo Pharma partners with clinical research organizations and academic institutions. Its involvement in pivotal Phase III trials ensures early access to innovative therapies, maintaining its competitive edge.

What Are Strategic Opportunities and Risks?

Growth in Emerging Markets

Market expansion in Asia-Pacific and Latin America offers high growth potential. Local regulatory pathways are more streamlined, but challenges include market entry barriers and local competition.

Digitalization and Personalized Medicine

The adoption of digital health platforms and biomarker-driven treatments is an emerging trend. Leo Pharma's investment in digital capabilities supports targeted therapies and remote patient monitoring.

Patent Expirations and Generic Competition

Several key products face patent cliffs by 2025, risking revenue declines. The company mitigates this with new product launches and pipeline diversification.

Regulatory Environment

Approval processes in the US, EU, and emerging markets pose delays and cost implications. Recent tightening of regulatory standards underscores the need for rigorous clinical data.

How Does Leo Pharma Compare to Key Competitors?

Company	Market Focus	Revenue (2022)	Notable Products	R&D Investment (Approx.)
Johnson & Johnson	Broad pharma & dermatology	$94.9 billion	Stelara, Tremfya	$11 billion (approx.)
Novartis	Broad, including dermatology	$51.6 billion	Cosentyx, Xolair	$10.4 billion
AbbVie	Focus on immunology and dermatology	$58.4 billion	Humira, Skyrizi	$6 billion
Leo Pharma	Niche focus, psoriasis, eczema, infections	$2.1 billion	Finacea, Kyntheum	$300 million (~15%) R&D

Leo Pharma's specialized portfolio results in a competitive advantage in niche indications but limits growth relative to broader-spectrum competitors.

What Are Immediate Strategic Recommendations?

1. Pipeline Acceleration: Prioritize late-stage biologic and small molecule candidates for faster market entry.
2. Market Expansion: Increase presence in Asia-Pacific and Latin America via partnerships and local subsidiaries.
3. Digital Transformation: Invest in digital health solutions and data analytics to enhance personalized therapies.
4. Intellectual Property Protection: Strengthen patent portfolios ahead of patent expirations to sustain revenue.
5. Collaborative Innovation: Expand alliances with biotech firms for microbiome and gene therapy solutions targeting dermatology.

Conclusion

Leo Pharma's competitive positioning relies on its niche specialization, targeted R&D, and regional strengths. To sustain growth, it must accelerate innovation, expand geographically, and adapt to digital trends while managing patent risks.

Key Takeaways

• Leo Pharma ranks as a top private dermatology player with a niche focus, generating over $2 billion annually.
• Its strengths include a targeted portfolio, significant R&D investments, and strategic acquisitions.
• Facing patent expirations and intense competition, Leo Pharma must innovate and expand in emerging markets.
• The company's pipeline and partnerships provide growth avenues, particularly in biologics and microbiome therapies.
• Strategic focus on digital health and personalized medicine will be critical to future competitiveness.

FAQs

1. What is Leo Pharma’s core market segment?
Dermatology, specifically psoriasis, eczema, and bacterial skin infections.

2. How much does Leo Pharma invest in R&D annually?
Approximately $300 million, representing around 15% of revenue.

3. Who are Leo Pharma’s main competitors?
Johnson & Johnson, Novartis, and AbbVie.

4. What are risks associated with Leo Pharma's growth?
Patent expirations, regulatory delays, and intense competition in core indications.

5. What strategic moves can enhance Leo Pharma’s market position?
Pipeline acceleration, geographic expansion, digital health investments, and IP strengthening.

---

References

[1] Bloomberg. (2023). Leo Pharma Financials and Market Data.
[2] IQVIA. (2022). Global Dermatology Market Analysis.
[3] Leo Pharma Annual Report. (2022).
[4] Evaluate Pharma. (2023). R&D Spending Reports.
[5] Statista. (2023). Market Share in Dermatology Pharmaceuticals.